Study details
Enrolling now
Progesterone to Enhance Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia
University of Mississippi Medical Center
NCT IDNCT02989025ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
60
Study length
about 9.7 years
Ages
18–45
Sex
Female only
Locations
1 site in MS
What this study is about
This trial is testing if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes. Mothers will receive 17 OHPC via injection every 7 days, along with blood samples collected at various times during pregnancy and after delivery.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take 17 OHPC
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Reproductive Health